Targeted Oncology7h
Response Time and BRAF Status Factor Into IO Selection for Melanoma
During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed how data from the CheckMate-067 and RELATIVITY-047 ...
Aethlon Medical Treats First Patient in Australian Hemopurifier® Cancer Trial
Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced a significant milestone: ...
Medical Therapeutic Stock Aethlon Medical, Inc. (NASDAQ: $AEMD) Gains On Cancer Clinical Trial Update
( MENAFN - Investor Ideas) Investorideas ( ), a go-to platform for big investing ideas for stock traders, including biotech and medical tech Stocks reports on trading and news for Aethlon Medical, Inc ...
Breaking Medical Technology News: Aethlon Medical (NASDAQ: AEMD) Treats First Patient In Australian Hemopurifier® Cancer Trial
Aethlon Medical, Inc. (Nasdaq: AEMD ), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious ...
Medscape22h
High-Income Nations Lead, Others Lag in Cancer Care Equity
Despite progress, significant disparities in cancer drug access persist globally, with low-income nations struggling to ...
Cure Today9h
Opdivo Plus Yervoy Improves Outcomes in Metastatic Colorectal Cancer Subset
The combination of Opdivo and Yervoy is supported by updated results as a standard of care for MSI-H or dMMR metastatic ...
precisionmedicineonline9h
Opdivo, Yervoy Outperform Single-Agent Immunotherapy in First-Line MSI-High, dMMR Colorectal Cancer
Data presented at the ASCO Gastrointestinal Cancers Symposium showed the regimen may be a new option, but it comes with more treatment and financial toxicity.